Report Finds FDA-Cleared Imaging Technology Improves Confidence in Breast Cancer Detection

Nov. 9, 2026 — DeepLook Medical has announced promising results from a new clinical study conducted at Oxford University Hospitals NHS Foundation Trust in the United Kingdom, demonstrating that its FDA-cleared DL Precise visual enhancement technology, improved radiologists' confidence in detecting breast cancer in dense breasts by 5.2% without increasing false-positive findings.

The study was led by Dr. Sarim Ather, Co-Director Oxford Clinical AI Research (OxCAIR) and Dr. Aya Deabes, Consultant Breast Radiologist.

The results address a longstanding challenge in breast imaging, particularly for women with dense breast tissue, which can make cancers more difficult to identify on traditional mammograms. Nearly half of women have dense breasts, highlighting the need for technologies that can help radiologists better identify suspicious findings.

In the study, four breast radiologists independently evaluated 400 diagnostic mammography cases with and without DL Precise. There was a measurable impact on the diagnostic confidence, particularly in the dense breast cohort where 35% of cancers initially called ‘indeterminate’ (M3) by the unaided reader were reclassified to confident ‘suspicious’ calls (M4+).

"For women with dense breasts, where identifying cancer can be especially challenging, technologies, like DL Precise™, that enhance image interpretation could play an important role in improving diagnostic confidence." said Dr. Aya Deabes, NHS Breast Imaging Consultant and Lead Clinical Investigator.

Breast Cancer Detection

Dense breast tissue is both a recognized risk factor for breast cancer and a challenge for mammographic interpretation. Dense tissue and many cancers appear white on mammograms, making suspicious findings difficult to distinguish from surrounding tissue.

DeepLook Medical’s DL Precise technology uses AI-powered image enhancement to improve visualization of the tissue and suspicious findings, providing radiologists with additional information to support clinical interpretation without requiring an additional scan to produce the enhanced images.

The study, Evaluating the Impact of the DL Precise Image Enhancement Tool on Mammographic Reading in the One Stop Breast Clinic, evaluated how the technology affected cancer detection, false-positive findings, biopsy recommendations, and interpretation time.

Key findings included:

• Reader diagnostic confidence improved: In dense and mixed-density breasts, 35% of cancers originally scored “intermediate” (M3) by the unaided reader were reclassified as “suspicious” (M4+) with DL Precise.  This represents a 5.2% increase in sensitivity.

• Preserved specificity: Specificity remained essentially unchanged, from 77.7% to 77.2%, indicating no meaningful increase in false-positive findings.

• Reading time: DL Precise added a median of minimal 13 seconds per diagnostic case.

• Greater consistency among radiologists: The spread between the highest and lowest reader-level sensitivities narrowed by 4.8 percentage points, consistent with readers converging on more standardized assessments.

"One of the greatest opportunities for AI in healthcare is empowering physicians with better information to make critical decisions, especially at the diagnostic evaluation stage," said Marissa Fayer, CEO of DeepLook Medical. "This study demonstrates the potential of our technology to help radiologists identify more cancers while maintaining accuracy and efficiency. Mammograms have so much grayscale information but the human eye just can't see it; applying DL Precise enhanced color visualization allows the best use of this high-resolution imaging for soft lesions.  For women, particularly those with dense breasts, advancements like these could help support more informed and timely diagnostic decisions."

The Future of Breast Imaging

The retrospective study was conducted at Oxford University Hospitals NHS Foundation Trust using 400 consecutive diagnostic mammography cases from the one-stop breast clinic. Four consultant breast radiologists reviewed cases with and without DL Precise, with cancer status established through pathology or two-year cancer-free follow-up.

The findings were presented at British Society of Breast Radiology (BSBR)  2026. They provide encouraging evidence that AI-powered image enhancement can improve radiologist performance in challenging mammographic cases while preserving specificity and limiting additional interpretation time.